You are here

DEVELOPMENT OF A BIOLOGICALLY-ACTIVE VASCULAR GRAFT

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42HL063511-02
Agency Tracking Number: HL063511
Amount: $0.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BIOMOD SURFACES 125 BRIDGE RD
SALISBURY, MA 01952
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MATTHEW PHANEUF
 (978) 465-0473
 DDEM764124@AOL.COM
Business Contact
 DONALD DEMPSEY
Phone: (978) 465-0967
Email: DDEM764124@AOL.COM
Research Institution
 BETH ISRAEL DEACONESS MEDICAL CENTER
 
BETH ISRAEL DEACONESS MEDICAL CENTER
SALISBURY, MA 02215
United States

 Domestic Nonprofit Research Organization
Abstract

Medium (6-8mm) and small (<5mm) internal diameter prosthetic grafts continue to have clinically unacceptable high failure rates. In phase I, an ionic polyurethane-sealed Dacron vascular graft (PEU-D) with reduced water permeation, excellent physical properties and co-valently bound anti-thrombin (recombinant hirudin of rHir) and mitogenic (vascular endothelial growth factor or VEGF) agents was developed. These surface bound agents were determined to be biologically active. Our objective in this proposal is to assess blood permeation and graft patency/healing of the PEU-D graft using a canine arterial grafting model. Our hypothesis is that implantation of this novel graft will prevent blood permeation thereby obviating the need for pre-clotting and improve graft patency and healing by emulating some of the natural properties of native vessels. The specific aims are to: 1) develop a batch synthesis for ionic polyurethane, 2) scale-up the process for sealing Dacron grafts, 3) evaluate PEU-D physical and chemical properties, 4) covalently link rHir and VEGF to PEU-D surface, 5) assess in vivo acute and chronic implantation periods and 6) examine macroscopically explanted grafts. Development of a polyurethane sealant with protein binding properties would have a significant role for medical devices such as vascular grafts catheters and artificial organs.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government